|Day Low/High||25.65 / 26.45|
|52 Wk Low/High||9.51 / 23.30|
Demographic trends that boosted big gains in prior years haven't gone away.
This is the time of the year when many moves are made for tax reasons.
The number of new 12-month highs has climbed to 240.
U.S. Court of Appeals Affirms District Court's Decision on Oxtellar XR®
Jim Cramer urges caution with phamaceutical companies Supernus and Ariad
Jim Cramer explains the rotation, looks ahead to next week.
In trading on Thursday, shares of Supernus Pharmaceuticals Inc crossed below their 200 day moving average of $18.67, changing hands as low as $18.00 per share. Supernus Pharmaceuticals Inc shares are currently trading off about 8.3% on the day.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
These small-caps are woefully undervalued after getting shellacked in October.
Given the biotech's growth prospects and pipeline assets, its shares seem greatly undervalued.
Look for sideways action, perhaps extending into third-quarter earnings season.
Buyers expect a dovish Fed and are still trying to put money to work.
Despite the unsettled market, there are still some interesting picks out there.
Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a new lifetime high candidate
Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a strong and under the radar candidate